These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

497 related items for PubMed ID: 25093620

  • 21. Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients.
    Ueda M, Inaba M, Okuno S, Nagasue K, Kitatani K, Ishimura E, Shimizu M, Miki T, Kim M, Nishizawa Y.
    Am J Kidney Dis; 2002 Oct; 40(4):802-9. PubMed ID: 12324916
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure.
    López Gavilanes E, González Parra E, de la Piedra C, Caramelo C, Rapado A.
    Miner Electrolyte Metab; 1994 Oct; 20(5):259-64. PubMed ID: 7700213
    [Abstract] [Full Text] [Related]

  • 24. Increase in circulating sclerostin at the early stage of menopausal transition in Japanese women.
    Matsui S, Yasui T, Kasai K, Keyama K, Kato T, Uemura H, Kuwahara A, Matsuzaki T, Irahara M.
    Maturitas; 2016 Jan; 83():72-7. PubMed ID: 26508082
    [Abstract] [Full Text] [Related]

  • 25. Tartrate-resistant acid phosphatase isoform 5a as an inflammation marker in end-stage renal disease.
    Janckila AJ, Lederer ED, Price BA, Yam LT.
    Clin Nephrol; 2009 Apr; 71(4):387-96. PubMed ID: 19356371
    [Abstract] [Full Text] [Related]

  • 26. Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density.
    Halleen JM, Ylipahkala H, Alatalo SL, Janckila AJ, Heikkinen JE, Suominen H, Cheng S, Väänänen HK.
    Calcif Tissue Int; 2002 Jul; 71(1):20-5. PubMed ID: 12073156
    [Abstract] [Full Text] [Related]

  • 27. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction.
    Yamada S, Inaba M, Kurajoh M, Shidara K, Imanishi Y, Ishimura E, Nishizawa Y.
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):189-96. PubMed ID: 18221403
    [Abstract] [Full Text] [Related]

  • 28. A distinct bone phenotype in ADPKD patients with end-stage renal disease.
    Evenepoel P, Claes K, Cavalier E, Meijers B, Stenvinkel P, Behets G, Jankowska M, D'Haese P, Bammens B.
    Kidney Int; 2019 Feb; 95(2):412-419. PubMed ID: 30665572
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism.
    Lu KC, Tseng CF, Wu CC, Yeung LK, Chen JS, Chao TY, Janckila AJ, Yam LT, Chu P.
    Blood Purif; 2006 Feb; 24(5-6):423-30. PubMed ID: 16888370
    [Abstract] [Full Text] [Related]

  • 33. Sclerostin declines during hemodialysis and appears in Dialysate.
    Bielesz BO, Hempfing T, Kieweg H, Marculescu R, Haas M, Cejka D.
    Blood Purif; 2014 Feb; 38(1):30-6. PubMed ID: 25228355
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Correlates of bone microarchitectural parameters and serum sclerostin levels in men: the STRAMBO study.
    Szulc P, Boutroy S, Vilayphiou N, Schoppet M, Rauner M, Chapurlat R, Hamann C, Hofbauer LC.
    J Bone Miner Res; 2013 Aug; 28(8):1760-70. PubMed ID: 23408601
    [Abstract] [Full Text] [Related]

  • 38. Biochemical markers of bone turnover and their relation to forearm bone mineral density in persons of Pakistani and Norwegian background living in Oslo, Norway: The Oslo Health Study.
    Holvik K, Meyer HE, Søgaard AJ, Selmer R, Haug E, Falch JA.
    Eur J Endocrinol; 2006 Nov; 155(5):693-9. PubMed ID: 17062885
    [Abstract] [Full Text] [Related]

  • 39. Two-year cortical and trabecular bone loss in CKD-5D: biochemical and clinical predictors.
    Malluche HH, Monier-Faugere MC, Blomquist G, Davenport DL.
    Osteoporos Int; 2018 Jan; 29(1):125-134. PubMed ID: 28993865
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.